Plain-English translation of NCT07690163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a continuous glucose monitoring (CGM) device—a small sensor worn on your body that tracks blood sugar 24/7—helps people with newly diagnosed Type 2 diabetes better control their condition compared to traditional fingerstick blood tests. The CGM gives you real-time information about how your food, activity, and sleep affect your blood sugar, which may motivate you to make healthier lifestyle choices. The study will follow you for 3 months to see if this device improves your blood sugar control and quality of life.
Most people with newly diagnosed Type 2 diabetes use fingerstick testing, which only shows isolated snapshots of blood sugar at certain moments and misses important fluctuations throughout the day. Early research suggests that real-time glucose monitoring might help people control their diabetes better and even prevent long-term complications, but this hasn't been thoroughly tested in newly diagnosed patients like you.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either wear a continuous glucose monitor or use a traditional fingerstick glucometer for 28 days. If you receive the monitor, you'll wear a small sensor on your skin that automatically tracks your blood sugar throughout the day and sends the data to your phone or device. If you're in the fingerstick group, you'll test your blood sugar 2–3 times per week using traditional finger pricks. Both groups will receive educational materials to help manage diabetes and will complete surveys before and after the 28-day monitoring period. You'll also have follow-up appointments and assessments for 3 months total.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Ukraine